Debiopharm Innovation Fund

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The company's platform streamlines processes by offering configurable workflows, a form builder for capturing complex and structured therapy-specific data, and tools for task management and tracking. Additionally, it integrates with machine learning libraries to enhance collaboration between manufacturers and physicians regarding requests for investigational medicines. MedaSystems focuses on various access programs, including expanded access, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby empowering global initiatives in the healthcare sector.

StratifAI is a precision oncology company that develops multimodal AI models to extract prognostic insights from routine histology images and clinical data. Their expertise lies in biomarker discovery, clinical trial data analysis, large language models, and multimodal data integration, aiming to guide treatment decisions and facilitate the development of personalized cancer therapies by pharmaceutical companies.

Risklick is a technology company that specializes in clinical trial risk assessment. It has developed a pioneering data-driven tool to help end-users identify similar clinical trials and evaluate risks during the initial stages of protocol design. This is crucial as up to 90% of clinical trials fail at this early stage, and the nature of these trials makes risk assessment challenging and time-consuming. Risklick's platform employs machine learning and artificial intelligence to analyze and mitigate risks, enabling data scientists, risk analysts, and clinical trial experts to support clinical trial designers in assessing risks during the design phase.

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The company's platform streamlines processes by offering configurable workflows, a form builder for capturing complex and structured therapy-specific data, and tools for task management and tracking. Additionally, it integrates with machine learning libraries to enhance collaboration between manufacturers and physicians regarding requests for investigational medicines. MedaSystems focuses on various access programs, including expanded access, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby empowering global initiatives in the healthcare sector.

OmicsChart is a technology company specializing in a data and biomarker discovery platform for cancer research. It aims to streamline precision oncology data sharing, fostering collaboration and accelerating clinical research. The platform unifies disparate cancer data, enabling secure, instantaneous patient data sharing and facilitating the scalable application of machine learning methods on real-world data. This ultimately expedites the journey from discovery to effective treatments, potentially saving years in the research process.

Altis Labs is a computational imaging company that specializes in advancing clinical trials through the use of artificial intelligence. The company has developed the industry's largest multimodal training database, which includes longitudinal imaging data linked to demographic, clinical, molecular information, and over 500,000 years of outcomes data. This extensive dataset is used to train prognostic AI models. Biopharmaceutical companies utilize Altis' software platform to process their clinical trial data in real time, enabling them to predict the efficacy of their drugs with greater confidence. This approach helps reduce the time and cost associated with bringing novel drugs to market by providing earlier and more accurate measurements of treatment effects from existing data.

Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.

Genialis, Inc. is a computational precision medicine company that specializes in the development of a web-based software platform for biological data management, analysis, visualization, and interpretation. Founded in 2011 and based in Houston, Texas, the company focuses on unraveling complex biology to discover actionable biomarkers that can enhance disease treatment. Its platform combines a range of visual analytics and bioinformatics tools, facilitating the storage and tracking of data while automating primary analyses to ensure reproducibility. Genialis enables non-experts to access sophisticated downstream analyses and supports secure sharing of data insights. The company's efforts aim to assist pharmaceutical and diagnostics companies in developing more effective drugs and deploying tests that improve treatment decisions, thereby increasing the probability of clinical success and validating therapeutic targets.

Iktos is a French scale-up company focused on applying artificial intelligence and robotic technologies to medicinal chemistry and drug design. The company has developed a proprietary generative AI solution that optimizes small molecules in silico, enhancing productivity in pharmaceutical research and development. Iktos offers its expertise through its SaaS platforms, Makya™ for generative drug design and Spaya™ for retrosynthesis, while also collaborating with pharmaceutical companies to accelerate drug discovery processes. Additionally, Iktos has created Iktos Robotics, an AI-driven automation platform that significantly speeds up the Design-Make-Test-Analyze cycle in drug discovery. The company is also advancing its own pipeline of drug candidates aimed at oncology and autoimmune diseases. In 2023, Iktos completed a significant financing round and, in 2024, expanded its capabilities through the acquisition of Synsight, integrating a biology platform focused on discovering new drugs that target Protein-Protein Interactions and RNA-Protein Interactions.

Yonalink operates a global network comprising over 30,000 medical centers. It specializes in real-time collection of clinical trial data through its platform, which streamlines electronic health records (EHR) to electronic data capture (EDC), employs AI-driven case report form (CRF) data mapping, and facilitates secure, automated migration of research data from health records. This service enhances trial efficiency, improves data quality, reduces staff burnout at medical centers, and expands access to novel patient care opportunities. Additionally, the platform enables management of clinical trial operations and vendors, accelerates drug and device development, promotes patient diversity and enrollment, and ensures secure, fast, and error-free data capture processes for healthcare providers and researchers.

Mika is a digital platform that empowers cancer patients. It aims to help improve cancer patients' mental health and well-being. Mika was created in collaboration with leading research institutions. The company was established in 2017 and is headquartered in Berlin, Germany.

VivoSense, also known as Vivonoetics, is a data analysis and software company that focuses on wearable sensor physiological monitoring solutions for research and clinical trials. The company develops innovative digital clinical measures aimed at enhancing patient clinical research and care. Its platform specializes in providing digital biomarkers derived from wearable sensor data, facilitating the collection of real-world data in regulated clinical trials. By enabling researchers to analyze this data accurately, VivoSense supports informed decision-making and risk evaluation associated with various medical treatments.

Nucleai Ltd. is a spatial biology company based in Tel Aviv-Yafo, Israel, founded in 2017. It has developed an AI-powered pathology platform that enhances drug development and improves patient outcomes by analyzing tissue datasets to provide insights into cancer biology. The platform is designed to detect various diseases, including cancer, prostate, breast, and gastrointestinal conditions, through advanced machine learning and computer vision techniques. By improving the interpretation of biopsies and supporting treatment decisions, Nucleai aims to increase the efficacy of clinical trials and enhance patient care. The company collaborates with leading pharmaceutical firms, licensing its technology for internal research and participating in biomarker discovery projects. Nucleai serves hospitals and laboratories primarily in the United States and Israel.

VeriSIM Life, Inc. is a biotechnology company based in San Francisco, California, established in 2017. It specializes in developing disease-specific biosimulation models that utilize artificial intelligence to predict the clinical outcomes of new drugs prior to clinical trials. The company offers a range of tailored solutions designed for pre-clinical and clinical programs, all centered around its validated BIOiSIM platform, which accommodates small molecules, large molecules, and viruses. By replacing traditional animal testing with sophisticated software simulations, VeriSIM Life aims to enhance the accuracy and efficiency of drug development, ultimately contributing to increased human life expectancy and the personalization of healthcare treatments.

Mekonos Inc. is a biotechnology company founded in 2017 and based in San Francisco, California, specializing in the design, development, and production of gene and cell therapies. The company has created a proprietary cell-engineering platform that utilizes a silicon chip automated architecture to advance the field of genome editing. This innovative system-on-a-chip technology allows for the precise control of individual nanoneedles to inject single cells in a parallel architecture, enabling the industrial-scale production of engineered therapies for a range of genetic diseases, including cancers. Mekonos aims to provide healthcare providers with a reliable and reusable manufacturing system that can deliver various therapeutic molecules across different primary cell types, thus enhancing drug discovery and development processes.

Carevive Systems, Inc. is a healthcare technology company that specializes in enhancing cancer care delivery through its innovative platform. The company offers Carevive PROmpt, a comprehensive software solution designed for treatment planning, patient engagement, symptom management, and survivorship care. This platform includes features such as electronic patient-reported outcomes (ePRO), care coordination tools, and analytics that help oncology practices adapt to value-based care models. Carevive Systems also provides a Risk Stratification model to identify at-risk patients and develops symptom management plans based on clinical data and evidence-based guidelines. Founded in 2013 and based in North Miami, Florida, Carevive Systems aims to improve clinical outcomes and patient experiences by delivering personalized and continuously updated cancer care plans.

Voluntis, established in 2001, specializes in developing digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. The company offers products such as Insulia, Diabeo, Oleena, and AstraZeneca, which provide automated insulin dose recommendations, patient-specific dosage suggestions, and management of side effects like hypertension and diarrhea. Voluntis collaborates with pharmaceutical companies like Bristol-Myers Squibb to co-develop digital therapeutics for oncology. With a patient-centric approach, Voluntis aims to enhance medical practices and improve healthcare system efficiency through secure, collaborative, and innovative digital health solutions.

Oncomfort SA is a Belgian company founded in 2017, specializing in digital sedation solutions aimed at alleviating pain and anxiety associated with medical procedures. It offers Sedakit, an all-in-one portable device that delivers a unique form of digital sedation therapy. This innovative approach integrates clinical hypnotherapy and various therapeutic techniques using virtual reality to provide evidence-based self-management solutions. By focusing on non-pharmacological methods, Oncomfort's technology helps patients cope with anxiety, stress, and the side effects of medical treatments, enhancing their comfort before, during, and after procedures. The company is headquartered in Wavre, Belgium.

Nucleai Ltd. is a spatial biology company based in Tel Aviv-Yafo, Israel, founded in 2017. It has developed an AI-powered pathology platform that enhances drug development and improves patient outcomes by analyzing tissue datasets to provide insights into cancer biology. The platform is designed to detect various diseases, including cancer, prostate, breast, and gastrointestinal conditions, through advanced machine learning and computer vision techniques. By improving the interpretation of biopsies and supporting treatment decisions, Nucleai aims to increase the efficacy of clinical trials and enhance patient care. The company collaborates with leading pharmaceutical firms, licensing its technology for internal research and participating in biomarker discovery projects. Nucleai serves hospitals and laboratories primarily in the United States and Israel.

Carevive Systems, Inc. is a healthcare technology company that specializes in enhancing cancer care delivery through its innovative platform. The company offers Carevive PROmpt, a comprehensive software solution designed for treatment planning, patient engagement, symptom management, and survivorship care. This platform includes features such as electronic patient-reported outcomes (ePRO), care coordination tools, and analytics that help oncology practices adapt to value-based care models. Carevive Systems also provides a Risk Stratification model to identify at-risk patients and develops symptom management plans based on clinical data and evidence-based guidelines. Founded in 2013 and based in North Miami, Florida, Carevive Systems aims to improve clinical outcomes and patient experiences by delivering personalized and continuously updated cancer care plans.

BC Platforms is a technology company that specializes in providing a unique data and technology platform for life sciences and healthcare companies. Their Data Access Platform offers access to valuable real-world data (RWD), clinical, genomics, and omics data through a data-as-a-service model. This enables pharmaceutical companies to enhance various use cases within the research and development continuum, from early discovery to post-market processes. The company's technology platform also supports healthcare providers and life science companies in producing, managing, and analyzing complex genomic data as a clinical decision-support solution. BC Platforms' Data Partner Network covers over 22 million life-years of highly curated patient data from around the world, ensuring compatibility with relevant technical standards and compliance with local privacy laws.

Kaiku Health Oy is a digital health company based in Helsinki, Finland, founded in 2012. The company specializes in developing user-centered software solutions that facilitate communication between patients, doctors, and nurses, particularly focusing on cancer care. Kaiku Health's platform enables the monitoring of patient-reported outcomes and utilizes intelligent algorithms for symptom tracking and early intervention, which enhances personalized patient support. It operates in multiple languages, including Swedish, English, German, and Finnish, and serves over 30 clinics and university hospitals across Finland, Sweden, and Switzerland. By streamlining workflows and optimizing care through real-time data capture and analysis, Kaiku Health aims to improve the quality of life for patients. The company, which was previously known as Netmedi Oy, changed its name in 2017 and is now a subsidiary of Elekta AB.

ABAC Therapeutics S.A., based in Barcelona, Spain, specializes in the development of precision antimicrobial agents specifically designed to combat multidrug-resistant (MDR) Gram-negative infections. Founded in 2014, the company employs its innovative drug discovery platform, PasNas, to identify pathogen-specific antibacterial properties of various molecules. This platform not only promotes compounds effective against MDR strains but also emphasizes the importance of incorporating favorable pharmacokinetic and toxicological characteristics early in the development process. By focusing on first-in-class drugs and leveraging new mechanisms of action, ABAC Therapeutics aims to provide scalable and effective therapeutic alternatives for patients afflicted by antibiotic-resistant bacterial pathogens, addressing a critical need in modern medicine. As of November 2019, ABAC Therapeutics operates as a subsidiary of Tibidabo Ventures.

BC Platforms is a technology company that specializes in providing a unique data and technology platform for life sciences and healthcare companies. Their Data Access Platform offers access to valuable real-world data (RWD), clinical, genomics, and omics data through a data-as-a-service model. This enables pharmaceutical companies to enhance various use cases within the research and development continuum, from early discovery to post-market processes. The company's technology platform also supports healthcare providers and life science companies in producing, managing, and analyzing complex genomic data as a clinical decision-support solution. BC Platforms' Data Partner Network covers over 22 million life-years of highly curated patient data from around the world, ensuring compatibility with relevant technical standards and compliance with local privacy laws.

Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and learning solutions tailored for employees. The company provides an innovative learning experience platform that offers a diverse catalog of training courses in the form of MOOCs. These courses consist of short sessions accessible at any time and on various devices, allowing users to engage with customized content that meets their specific learning needs. Coorpacademy aims to revolutionize digital learning by enhancing accessibility and personalization in employee training.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

KeyLemon S.A., established in 2008 in Martigny, Switzerland, specializes in biometric authentication solutions. The company pioneered face recognition technology for natural and passive user identification, aiming to enhance security while ensuring convenience. KeyLemon's flagship product, Oasis, enables mobile authentication via face recognition, serving clients globally across various industries. Since its founding by Gilles Florey and Yann Rodriguez, the company has remained committed to improving secure access to high-value transactions, operating as a subsidiary of ams AG since 2018.

Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.

Searchbox is a software company specializing in search technologies, with strong areas of expertise in cognitive sciences, data mining and computer sciences. Through its innovative technologies, Searchbox fundamentally changes the way people interact and consume information. Through highly customizable cloud based search solutions and plugins for Solr, these technologies are readily available for usage with a minimal amount of tinkering.

Neovacs is a biotechnology company founded in 1993 as a spin-off from the Pierre & Marie Curie University in Paris by Professor Daniel Zagury, a prominent immunologist. The company specializes in the development of therapeutic vaccines known as "Kinoids," which are designed to treat a range of conditions including autoimmune diseases, allergies, and cancer. Neovacs holds an extensive patent portfolio and is recognized for its innovative approach to vaccine development, particularly in creating vaccines that target human cytokines and immunosuppressive viral proteins. Unlike traditional monoclonal antibody treatments that provide exogenous therapies, Neovacs' therapeutic vaccines promote a robust natural polyclonal antibody response in patients, positioning the company as a pioneer in the field of immunotherapy.